For better or for worse (but mostly for better), COVID-19 has taken Novavax (NVAX) on a very wild ride.Since the first report of an infection with COrona VIrus Disease 2019 in Wuhan, China on December 31, 2019, shares of vaccine specialist Novavax literally quadrupled in the space of two months, topping out at $16 a share on February 28, before giving back some of its gains in March. In a note issued yesterday, Oppenheimer analyst Kevin DeGeeter reiterated his “outperform” call on Novavax stock, stating a price target of $13 a share on the $10 stock. DeGeeter explained his continued …read more
Source:: Yahoo Finance
